Sarepta Therapeutics Inc
NASDAQ: SRPT
$114.32
-$3.52 (-3.0%)
Closing Price on November 12, 2024
SRPT Articles
Tuesday’s top analyst upgrades and downgrades included Bilibili, Carvana, Crocs, GameStop, Goldman Sachs, Nike, Sarepta Therapeutics, Vir Biotechnology and Weber.
Published:
Friday afternoon's analyst upgrades and downgrades included BigCommerce, Citrix, GlaxoSmithKline, Nikola, Regeneron, Shake Shack and more.
Published:
Wednesday’s top analyst upgrades and downgrades included Alcoa, Caesars Entertainment, Chevron, DraftKings, Lucid, Sarepta Therapeutics, SoFi Technologies and Wynn Resorts.
Published:
Thursday’s top analyst upgrades and downgrades included Avis Budget, Chewy, Danaher, Eli Lilly, Etsy, Fastly, Halliburton, Robinhood, Roku, Walmart and Western Digital.
Published:
Tuesday’s top analyst upgrades and downgrades included Campbell Soup, Exact Sciences, Exelixis, Pool, Spirit Airlines and ZTO Express.
Published:
Monday's top analyst upgrades and downgrades included Best Buy, Discover Financial, Dollar General, Etsy, HCA Healthcare, KeyCorp, Simon Property, ViacomCBS and Weyerhaeuser.
Published:
Friday's top analyst upgrades and downgrades included Aflac, CME, Chevron, CVS Health, D.R. Horton, Goodyear Tire and Rubber, Lam Research, Micron Technology and U.S. Steel.
Published:
Tuesday's top analyst upgrades and downgrades included Crocs, Gap, GW Pharmaceuticals, Lowe's Companies, Merck, Nio, Palo Alto Networks, Phillips 66, Starbucks and Vital Farms.
Published:
Selecta Biosciences and Sarepta Therapeutics have announced that they had entered into a research license and option agreement.
Published:
Here are the biotech companies with exposure to experimental vaccines whose shares saw the biggest boost from this past week's coronavirus news.
Published:
China is facing an outbreak of the coronavirus, which may have spread to a few other countries in Asia. As a result, experimental vaccine stocks are skyrocketing.
Published:
Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this...
Published:
Christmas Eve's top analyst upgrades, downgrades and initiations included Amgen, Apple, Builder FirstSource, CarMax, Dominion Energy, FedEx, Nike, Regeneron Pharmaceuticals and Sarpeta Therapeutics.
Published:
Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy.
Published:
Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients.
Published: